KDM4C silencing inhibits cell migration and enhances radiosensitivity by inducing CXCL2 transcription in hepatocellular carcinoma

[1]  Yuanliang Yan,et al.  Application of genomic selection and experimental techniques to predict cell death and immunotherapeutic efficacy of ferroptosis-related CXCL2 in hepatocellular carcinoma , 2022, Frontiers in Oncology.

[2]  F. Heidel,et al.  Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms , 2022, Leukemia.

[3]  C. Yuh,et al.  Inhibition of KDM4C/c‐Myc/LDHA signalling axis suppresses prostate cancer metastasis via interference of glycolytic metabolism , 2022, Clinical and translational medicine.

[4]  Tao Zhang,et al.  Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer , 2022, Journal for ImmunoTherapy of Cancer.

[5]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[6]  J. Qiu,et al.  Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells , 2021, Signal Transduction and Targeted Therapy.

[7]  Shanshan Li,et al.  Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression , 2021, Hepatology.

[8]  Xu Peng,et al.  GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2 , 2021, Cell Death & Disease.

[9]  Shuangbing Xu,et al.  USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription , 2021, Cell Death & Differentiation.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  Junjeong Choi,et al.  Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc , 2021, Cell death & disease.

[12]  Y. Kaneda,et al.  CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy , 2020, Molecular therapy oncolytics.

[13]  Shuangbing Xu,et al.  CDK5 activates Hippo signaling to confer resistance to radiotherapy via upregulating TAZ in lung cancer. , 2020, International journal of radiation oncology, biology, physics.

[14]  Jing Wang,et al.  Wnt-Induced Stabilization of KDM4C Is Required for Wnt/β-Catenin Target Gene Expression and Glioblastoma Tumorigenesis. , 2019, Cancer research.

[15]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[16]  Bin Huang,et al.  CXCL2 attenuates osteoblast differentiation by inhibiting the ERK1/2 signaling pathway , 2019, Journal of Cell Science.

[17]  Xiaoliang Chen,et al.  Krüppel‐like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway , 2019, Cancer science.

[18]  R. Alon,et al.  Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis , 2018, Immunity.

[19]  Haiyang Xie,et al.  Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma , 2018, BMB reports.

[20]  B. Chiang,et al.  The KDM4A/KDM4C/NF-κB and WDR5 epigenetic cascade regulates the activation of B cells , 2018, Nucleic acids research.

[21]  William A. Flavahan,et al.  Epigenetic plasticity and the hallmarks of cancer , 2017, Science.

[22]  Jian Wu,et al.  High expression of hexokinase domain containing 1 is associated with poor prognosis and aggressive phenotype in hepatocarcinoma. , 2016, Biochemical and biophysical research communications.

[23]  Shuang Huang,et al.  KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism. , 2016, Cell reports.

[24]  Boris Lenhard,et al.  Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia , 2016, Cancer cell.

[25]  H. Aburatani,et al.  Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. , 2013, Carcinogenesis.

[26]  Andrew P. Feinberg,et al.  Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host , 2013, Nature Reviews Cancer.

[27]  R. Janknecht,et al.  KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. , 2013, Cancer research.

[28]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[29]  T. Mohr,et al.  Up‐regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis , 2011, Hepatology.

[30]  S. Ye,et al.  Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum , 2010, Journal of Cancer Research and Clinical Oncology.

[31]  M. J. van de Vijver,et al.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer , 2009, Oncogene.

[32]  T. Jenuwein,et al.  Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression , 2007, Nature Cell Biology.

[33]  Juri Rappsilber,et al.  The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3 , 2006, Nature.

[34]  Y. Nakamura,et al.  Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. , 2000, Cancer research.

[35]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[36]  J. Saiz,et al.  Right‐sided non‐recurrent laryngeal nerve without any vascular anomaly: an anatomical trap , 2021, ANZ journal of surgery.